組織工程・細胞療法・移植：全球的產品、技術、市場商機（2009∼2018年）

組織工程・細胞療法・移植：全球的產品、技術、市場商機（2009∼2018年） 是由出版商MedMarket Diligence在2010年02月所出版的。 這份英文市場調查報告書包含320 pages, 71 Exhibits, 147 Company Profiles 價格從美金2850起跳。

簡介

本報告，針對組織工程、細胞療法、組織移植／細胞移植市場的現狀與技術發展趨勢，以及當前的市場規模與今後的預測等，以領域別進行彙整，由下列摘要形式闡述。

報告摘要

第1章 組織工程與細胞療法業界的背景

• 概述
• 定義
• 主要程序
• 發展上的課題
• 臨床上的需求不足
• 組織工程以及細胞療法上的商業模式
• 時間表
• 該領域的課題
• 競爭激烈

第2章 臨床疾病與治療需求

• 簡介
• 癌症
• 牙科
• 耳鼻喉科／呼吸器官／心肺
• 胃腸科
• 婦科
• 神經科
• 眼科
• 器官移植
• 整形外科
• 皮膚／外皮
• 泌尿科

第3章 產品以及企業贊助的技術開發（已認可的與開發中的）

• 簡介
• 癌症
• 心血管・血管
• 牙科
• 耳鼻喉科／呼吸器官／心肺
• 胃腸科
• 婦科
• 神經科
• 眼科
• 器官移植以及相關療法
• 整形外科
• 皮膚／外皮
• 泌尿科

第4章 市場、潛在市場、競爭企業的市佔率

• 全球的組織工程產品市場

第5章 企業檔案資料（147家）

附錄

目錄

Abstract

This report examines the status of technologies, applications and markets for tissue engineering, cell therapy and tissue/cell transplantation. The report reviews therapeutic tissue engineering, tissue reconstruction, cell therapies, tissue/organ transplantation and related technologies under various stages of development at nearly150 companies. The report details the technology development, projected market introduction dates and/or current and forecast market size and competitor shares for products being developed to address major causes of death and disease spanning applications in cardiovascular, neurological, orthopaedic, urological, skin, dental, ophthalmological, gastrointestinal, organ transplant, cancer and others. The report details the status of product development and assesses the current and forecast worldwide market for tissue engineering, cell therapy and transplantation.

The report provides market size and share data, with forecast market data to 2018, for the U.S., Europe, Asia/Pacific and Rest of World.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast and assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

Report Statistics:

• 312 pages
• 74 Exhibits
• 147 Company Profiles

Table of Contents

Executive Summary

Section 1: TISSUE ENGINEERING AND CELL THERAPY INDUSTRY BACKGROUND

• 1.1 Overview
• 1.2 Definitions
• 1.3 Growth of Key Procedures
• 1.4 Development Challenges
  • 1.4.1 Material-based Tissue Replacements
  • 1.4.2 Allograft-derived Tissue Replacements
  • 1.4.3 Cell and Tissue Engineered Products
• 1.5 Unmet Clinical Needs
• 1.6 Business Models Based On Tissue Engineering and Cell Therapy
• 1.7 Timescales
• 1.8 Sector Challenges
  • 1.8.1 Reimbursement
  • 1.8.2 Regulatory
    • 1.8.2.1 United States
    • 1.8.2.2 China
    • 1.8.2.3 European Union
  • 1.8.3 Cost-effectiveness
  • 1.8.4 Clinical Issues
  • 1.8.5 Economic Downturns Worldwide
• 1.9 Competition Intensity
  • 1.9.1 Industry Focus
  • 1.9.2 Investment Levels
  • 1.9.3 Investor Returns

Section 2: Clinical Disorders and Therapy Needs

• 2.1 Introduction
  • 2.1.1 Stem Cell Banking
  • 2.1.2 Cardiovascular and Vascular
  • 2.1.3 Coronary Heart Disease
  • 2.1.4 Myocardial Infarction
  • 2.1.5 Congestive Heart Failure
  • 2.1.6 Dysfunctional Heart Valves
  • 2.1.7 Peripheral Vascular Disorders
  • 2.1.8 Abdominal Aortic Aneurysm
• 2.2 Cancer
  • 2.2.1 Urology
    • 2.2.1.1 Bladder
    • 2.2.1.2 Kidney/Renal Cell
    • 2.2.1.3 Prostate
  • 2.2.2 Neurology
  • 2.2.3 Ob/Gyn
    • 2.2.3.1 Breast
    • 2.2.3.2 Ovarian
    • 2.2.3.3 Endometrial
    • 2.2.3.4 Cervix Uteri
  • 2.2.4 Orthopedic/Bone
  • 2.2.5 Gastrointestinal/Gastroenterology
    • 2.2.5.1 Colorectal
    • 2.2.5.2 Gastric
    • 2.2.5.3 Pancreas
    • 2.2.5.4 Liver
    • 2.2.5.5 Esophageal
  • 2.2.6 Head and Neck
    • 2.2.6.1 Oral
    • 2.2.6.2 Throat
    • 2.2.6.3 Thyroid
  • 2.2.7 Hematopoietic
    • 2.2.7.1 Leukemia
    • 2.2.7.2 Lymphoma
  • 2.2.8 Respiratory
    • 2.2.8.1 Lung
  • 2.2.9 Dermatology (Skin Cancer)
• 2.3 Dental
  • 2.3.1 Missing Teeth
  • 2.3.2 Periodontal Disease
• 2.4 ENT/Respiratory/Cardiopulmonary
• 2.5 Trachea
  • 2.5.1 Respiratory Epithelial Cells
• 2.6 Gastrointestinal
  • 2.6.1 Esophagus
  • 2.6.2 Colon/Small Intestine
• 2.7 Gynecology
• 2.8 Neurological
  • 2.8.1 Stroke
  • 2.8.2 Parkinson' s Disease
  • 2.8.3 Alzheimer' s Disease
  • 2.8.4 Epilepsy
  • 2.8.5 Traumatic Brain Injury
  • 2.8.6 Central Nervous System and Spinal Cord Disease
    • 2.8.6.1 Amyotrophic Lateral Sclerosis
    • 2.8.6.2 Multiple Sclerosis
    • 2.8.6.3 Neuromuscular/Muscular Dystrophy
• 2.9 Ophthalmology
  • 2.9.1 Cornea
  • 2.9.2 Retina
• 2.10 Organ Transplantation
  • 2.10.1 Liver
  • 2.10.2 Heart
  • 2.10.3 Kidney
  • 2.10.4 Pancreas
• 2.11 Orthopedic
  • 2.11.1 Non-Union Fractures
  • 2.11.2 Cartilage Damage and Repair
  • 2.11.3 Ligament Damage
  • 2.11.4 Vertebral Disc Damage
  • 2.11.5 Bone Graft Materials
• 2.12 Skin/Integumentary
  • 2.12.1 Burns
  • 2.12.2 Diabetic Ulcers
  • 2.12.3 Venous Ulcers
  • 2.12.4 Plastic and Reconstructive Surgery
• 2.13 Urological
  • 2.13.1 Incontinence
  • 2.13.2 Kidney Disease
  • 2.13.3 Bladder

Section 3: Product & Company-Sponsored Technology Developments (Approved and in Development)

• 3.1 Introduction
• 3.2 Cancer
  • 3.2.1 Types of Cancer Gene Therapies
  • 3.2.2 Direct Delivery of Gene Proteins to Tumor
  • 3.2.3 Medications to Boost the Immune System/Antibodies
  • 3.2.4 Anti-Angiogenesis
  • 3.2.5 Vaccines
  • 3.2.6 Expanded Numbers of Cord Blood Stem Cells
• 3.3 Cardiovascular and Vascular
• 3.4 Dental
• 3.5 ENT/Respiratory/Cardiopulmonary
• 3.6 Gastrointestinal
• 3.7 Gynecology
• 3.8 Neurological
• 3.9 Ophthalmology
• 3.10 Organ Transplantation and Related Therapies
  • 3.10.1 Liver
  • 3.10.2 Kidney
  • 3.10.3 Pancreas/Diabetes Therapies
  • 3.10.4 Cryopreservation of Cells and Tissues
• 3.11 Orthopedic
• 3.12 Skin/Integumentary
  • 3.12.1 Plastic and Reconstructive Surgery
• 3.13 Urological

Section 4: Markets, Potential Markets, and COMPETITOR SHARES

• 4.1 Worldwide Potential Market for Tissue Engineered Products
• 4.2 Cardiovascular and Vascular
• 4.3 Neurological
• 4.4 Orthopedic
• 4.5 Urological
• 4.6 Skin/Integumentary
• 4.7 Dental
• 4.8 Organ Transplantation and Preservation
• 4.9 Ophthalmology
• 4.10 General, Gastrointestinal, Gynecologic and Other
• 4.11 Cancer
• 4.12 Cord Blood and Cell Banking

Section 5: Company profiles

• 5.1 3DM Inc.
• 5.2 Aastrom Bioscience Inc.
• 5.3 Acorda Therapeutics Inc.
• 5.4 Advanced BioHealing, Inc.
• 5.5 Advanced Cell Technology, Inc.
• 5.6 Advanced Medical Solutions PLC
• 5.7 Aeolus Pharmaceuticals
• 5.8 Aldagen, Inc.
• 5.9 Alexion Pharmaceuticals
• 5.10 Angioblast Systems, Inc.
• 5.11 Angiotech Pharmaceuticals, Inc.
• 5.12 Ariad Pharmaceuticals Inc.
• 5.13 Arteriocyte Medical Systems, Inc.
• 5.14 Athersys, Inc.
• 5.15 Avax Technologies Inc.
• 5.16 Avita Medical Limited
• 5.17 Baxter International Inc.
• 5.18 BeFutur Biotechnologies
• 5.19 Bio Nova International
• 5.20 Biocomposites
• 5.21 Biocoral Inc.
• 5.22 Bioheart Inc.
• 5.23 BioHybrid Technologies
• 5.24 BioLife Solutions Inc.
• 5.25 Biomet, Inc.
• 5.26 BioMimetic Therapeutics
• 5.27 BioSante Pharmaceuticals, Inc.
• 5.28 BioSyntech
• 5.29 BioTissue Technologies GmbH
• 5.30 Boston Scientific Corporation
• 5.31 BrainStorm Cell Therapeutics, Inc.
• 5.32 Breonics Perfusion Technologies, Inc.
• 5.33 BTG International Ltd.
• 5.34 California Stem Cells Inc.
• 5.35 Capstone Therapeutics
• 5.36 Celgene Corporation
• 5.37 CellECT Bio Inc.
• 5.38 Cellerix SA
• 5.39 CellSeed, Inc.
• 5.40 CellTran Ltd.
• 5.41 Cellular Dynamics International
• 5.42 Centocor Ortho Biotech, Inc.
• 5.43 Cerco Medical
• 5.44 co.don AG
• 5.45 ConMed Linvatec
• 5.46 Cook Group
• 5.47 CorCell Companies, Inc.
• 5.48 Cryo-Cell International, Inc.
• 5.49 CryoLife, Inc.
• 5.50 Curis Inc.
• 5.51 Cyclacel Pharmaceuticals, Inc.
• 5.52 Cytograft Tissue Engineering
• 5.53 Cytomatrix LLC
• 5.54 Cytori Therapeutics Inc.
• 5.55 ES Cell International
• 5.56 Exactech, Inc.
• 5.57 Excorp Medical, Inc.
• 5.58 FibroGen, Inc.
• 5.59 Fidia Advanced Biopolymers/Anika Therapeutics, Inc.
• 5.60 Forticell Bioscience, Inc.
• 5.61 Gamida Cell Ltd.
• 5.62 Garnet BioTherapeutics
• 5.63 Genta, Inc.
• 5.64 GenVec, Inc.
• 5.65 Genzyme Corporation
• 5.66 Geron Corporation
• 5.67 Glycotex, Inc.
• 5.68 HepaLife Technologies, Inc.
• 5.69 Hospira
• 5.70 Humacyte, Inc.
• 5.71 InCytu Inc.
• 5.72 Inion Ltd.
• 5.73 Innogenetics
• 5.74 InnovaCell Biotechnologie GmbH
• 5.75 Integra LifeSciences Inc.
• 5.76 ISTO Technologies Inc.
• 5.77 Johnson & Johnson Inc.
  • 5.77.1 Ethicon Biosurgery
  • 5.77.2 DePuy
• 5.78 Kensey Nash
• 5.79 Kerecis EHF
• 5.80 LifeCell Inc.
• 5.81 LifeStem Inc. (Calba Tech, Inc.)
• 5.82 Living Cell Technologies Ltd.
• 5.83 Lonza Group Ltd.
• 5.84 MaxCyte
• 5.85 Medtronic
• 5.86 Mesoblast Limited
• 5.87 MG Biotherapeutics, LLC
• 5.88 MicroIslet Inc.
• 5.89 Miltenyi Biotec
• 5.90 Musculoskeletal Transplant Foundation
• 5.91 Natural Implant
• 5.92 NellOne Therapeutics, Inc.
• 5.93 NeoStem, Inc.
• 5.94 Neuralstem, Inc.
• 5.95 NeuroGeneration, Inc.
• 5.96 NeuroNova AB
• 5.97 Neurotech
• 5.98 Novartis International AG
• 5.99 Novo Nordisk A/B
• 5.100 Novocell Inc.
• 5.101 OncoMed Pharmaceuticals
• 5.102 Organogenesis Inc.
• 5.103 Organovo, Inc.
• 5.104 Orthovita
• 5.105 OSI Pharmaceuticals
• 5.106 Osiris Therapeutics Inc.
• 5.107 Osteotech, Inc.
• 5.108 Pioneer Surgical Technologies
• 5.109 Pluristem Therapeutics Inc.
• 5.110 Poly-Med, Inc.
• 5.111 Polyganics BV
• 5.112 ProChon Biotech, Ltd.
• 5.113 Progenitor Cell Therapy Inc.
• 5.114 ProNeuron Biotechnologies, Inc.
• 5.115 Protein Polymer Technologies Inc.
• 5.116 ReGen Biologics Inc.
• 5.117 Reinnervate Ltd.
• 5.118 ReNeuron Ltd.
• 5.119 Revivicor, Inc.
• 5.120 RTI Biologics, Inc.
• 5.121 Sanofi-Aventis
• 5.122 Sciperio Inc.
• 5.123 Serica Technologies, Inc./Allergan
• 5.124 Sernova Corp.
• 5.125 Smith & Nephew Ltd.
• 5.126 SpineSmith Partners, LP
• 5.127 Stem Cell Pharma Inc.
• 5.128 Stem Cell Sciences UK Ltd.
• 5.129 Stem Cell Therapy International, Inc./Histostem Co. Ltd.
• 5.130 StemCell Technologies Inc.
• 5.131 StemCells Inc.
• 5.132 Stryker Corporation
• 5.133 Synovis Life Technologies, Inc.
• 5.134 Targeted Genetics Corporation
• 5.135 TEI Biosciences Inc.
• 5.136 Tengion, Inc .
• 5.137 Tepha Inc.
• 5.138 Theracell, Inc.
• 5.139 ThermoGenesis Corp.
• 5.140 TiGenix N.V.
• 5.141 Transition Therapeutics Inc.
• 5.142 TriStem Corporation
• 5.143 Vesta Therapeutics
• 5.144 ViaCell/PerkinElmer
• 5.145 Vital Therapies, Inc.
• 5.146 Vitrolife AB
• 5.147 Zimmer, Inc.

Appendix: Company Directory

List of Exhibit

• Exhibit ES-1: Worldwide Tissue Engineering & Cell Therapy Market, 2009-2018
• Exhibit ES-2: Worldwide Tissue Engineering & Cell Therapy Market, by Geographic Segment, 2009-2018
• Exhibit ES-3: Worldwide Tissue Engineering & Cell Therapy Market, By Segment, 2009-2018
• Exhibi ES-4: Worldwide Tissue Engineering & Cell Therapy Market by Manufacturer, 2009
• Exhibit 2-1: Leading Companies in Stem Cell Banking
• Exhibit 2-2: Potential For Cardiovascular Tissue Engineering - Incidences of Applicable Surgical Procedures, 2010
• Exhibit 2-3: Prevalence of Cardiovascular Disease in Adults Age 20 and Older by Age and Sex, Percent of the Population, 2003 - 2006
• Exhibit 2-4: Incidence of Cardiovascular Disease by Age and Sex, Per 1,000 Person Years, 1980 - 2003
• Exhibit 2-5: Incidence of Myocardial Infarction by Age and Sex, 1987 - 2004
• Exhibit 2-6: Prevalence of Heart Failure in the United States by Age and Sex, Percent of Population
• Exhibit 2-7: Incidence of New Cancer Cases Worldwide by Region, 2007
• Exhibit 2-8: Female Breast Cancer Incidence and Mortality Rates by Race and Ethnicity in the U.S., 2002 - 2006, Rate per 100,000
• Exhibit 2-9: Colorectal Cancer Incidence and Mortality Rates by Race/Ethnicity and Sex in the U.S., 2001 - 2005, Rate per 100,000
• Exhibit 3-1: Companies with Cancer Therapies Marketed or in Development
• Exhibit 3-2: Key Competitors in Tissue Engineering and Cell Therapies for Cardiovascular Applications
• Exhibit 3-3: Key Competitors in Tissue Engineering and Cell Therapies for Dental and Oral Surgery Applications
• Exhibit 3-4: Key Competitors in Tissue Engineering and Cell Therapies for ENT, Respiratory and Cardiopulmonary Applications
• Exhibit 3-5: Key Competitors in Tissue Engineering and Cell Therapies for Gastrointestinal Applications
• Exhibit 3-6: Key Competitors in Tissue Engineering and Cell Therapies for Gynecology Applications
• Exhibit 3-7: Key Competitors in Tissue Engineering and Cell Therapies for Neurology Applications
• Exhibit 3-8: Key Competitors in Tissue Engineering and Cell Therapies for Ophthalmology Applications
• Exhibit 3-9: Key Competitors in Tissue Engineering and Cell Therapies for Organ Transplant, Organ Preservation and Related Therapies
• Exhibit 3-10: Key Competitors in Tissue Engineering and Cell Therapies for Orthopedic, Musculoskeletal, and Spine Applications
• Exhibit 3-11: Key Competitors in Tissue Engineering and Cell Therapies for Skin/Integumentary Applications
• Exhibit 3-11: Key Competitors in Tissue Engineering and Cell Therapies for Urological Applications
• Exhibit 4-1: Worldwide Tissue Engineering & Cell Therapy Market, 2009-2018
• Exhibit 4-2: Worldwide Tissue Engineering & Cell Therapy Market, by Geographic Segment, 2009-2018
• Exhibit 4-3: Worldwide Tissue Engineering & Cell Therapy Market, By Segment, 2009-2018
• Exhibit 4-4: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, 2009-2018
• Exhibit 4-5: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, by Geographic Segment, 2009-2018
• Exhibit 4-6: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, by Manufacturer, 2009
• Exhibit 4-7: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, 2009-2018
• Exhibit 4-8: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, by Geographic Segment, 2009-2018
• Exhibit 4-9: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, by Manufacturer, 2009
• Exhibit 4-10: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, 2009-2018
• Exhibit 4-11: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, by Geographic Segment, 2009-2018
• Exhibit 4-12: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, by Manufacturer, 2009
• Exhibit 4-13: Worldwide Tissue Engineering & Cell Therapy Market, Urology, 2009-2018
• Exhibit 4-14: Worldwide Tissue Engineering & Cell Therapy Market, Urology, by Geographic Segment, 2009-2018
• Exhibit 4-15: Worldwide Tissue Engineering & Cell Therapy Market, Urology, by Manufacturer, 2009
• Exhibit 4-16: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, 2009-2018
• Exhibit 4-17: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, by Geographic Segment, 2009-2018
• Exhibit 4-18: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, by Manufacturer, 2009
• Exhibit 4-19: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, 2009-2018
• Exhibit 4-20: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, by Geographic Segment, 2009-2018
• Exhibit 4-21: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, by Manufacturer, 2009
• Exhibit 4-22: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, 2009-2018
• Exhibit 4-23: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, by Geographic Segment, 2009-2018
• Exhibit 4-24: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, by Manufacturer, 2009
• Exhibit 4-25: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, 2009-2018
• Exhibit 4-26: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, by Geographic Segment, 2009-2018
• Exhibit 4-27: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, by Manufacturer, 2009
• Exhibit 4-28: Worldwide Tissue Engineering & Cell Therapy Market, General, Gastroenterology, Gynecology, Others, 2009-2018
• Exhibit 4-29: Worldwide Tissue Engineering & Cell Therapy Market, General, Gastroenterology, Gynecology, Others, by Geographic Segment, 2009-2018
• Exhibit 4-30: Worldwide Tissue Engineering & Cell Therapy Market, General, GI, Gyn, Others, by Manufacturer, 2009
• Exhibit 4-31: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, 2009-2018
• Exhibit 4-32: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, by Geographic Segment, 2009-2018
• Exhibit 4-33: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, by Manufacturer, 2009
• Exhibit 4-34: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, 2009-2018
• Exhibit 4-35: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, by Geographic Segment, 2009-2018
• Exhibit 4-36: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, by Manufacturer, 2009
• Exhibit 5-1: Advanced Cell Technology, Inc. and Subsidiary Consolidated Statements of Operations for the Years Ended December 31, 2008 and 2007
• Exhibit 5-2: Clinical Trials Being Conducted by Mesoblast and Angioblast
• Exhibit 5-3: Angioblast' s Lead Products in Development
• Exhibit 5-4: Baxter Sales by Business, 2008, $ Billions
• Exhibit 5-5: BTG International' s Revenue-Producing Products and Sales Data
• Exhibit 5-6: Celgene' s Leading Product Candidates
• Exhibit 5-7: CryoLife Revenue by Product, 2008
• Exhibit 5-8: Genzyme Approved/Marketed Cell Therapy - Derived Products
• Exhibit 5-9: Geron' s hESC-derived Product Candidates
• Exhibit 5-10: Osteotech Revenues, Year End 2006 - 2008 (000)
• Exhibit 5-11: Proneuron' s Developmental Product Pipeline
• Exhibit 5-12: RTI Biologics' Revenues, Years Ended Dec. 31, 2006 - 2008, (000)
• Exhibit 5-13: RTI Biologics' Products by Distributor
• Exhibit 5-14: TEI Biosciences' Products, Applications and Marketing Partners

相關商品

細胞療法相關市場調查報告書

細胞治療:技術˙市場˙企業

Cell Therapy - Technologies, Markets and Companies

價格 : US $ 5500

出版日期 : 2012年04月

個別化醫療：科學的・商業的情勢

Personalized Medicine - scientific & commercial aspects

價格 : US $ 5000

出版日期 : 2012年04月

RNAi（RNA干擾）：技術、市場、企業

RNAi - technologies, markets and companies

價格 : US $ 4000

出版日期 : 2012年04月

MedMarket Diligence發行的生物科技相關市場調查報告書

全球整形外科用生物材料市場之最新趨勢、技術及機會

Emerging Trends, Technologies and Opportunities in the Markets for Orthopedic Biomaterials, Worldwide

價格 : US $ 2450

出版日期 : 2006年12月

全球的微米醫療與奈米醫療：技術、應用、產業、市場

Micro- and Nano-Medicine: Technologies, Applications, Industry, and Markets Worldwide

價格 : US $ 1650

出版日期 : 2006年05月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!